Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Patient characteristics and treatment outcomes in marginal zone lymphoma: results of the prospective German MZL registry.

Leukemia·2026

Same author

<i>Erratum</i> to: "Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance".

Haematologica·2025

Same author

Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial.

The Lancet. Oncology·2025

Same author

Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance.

Haematologica·2025

Same author

Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma.

Blood advances·2025

Search research articles

Related Experiment Video

Updated: Dec 3, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

[Perspectives on CAR T-cell treatment].

Andreas Viardot¹

¹Klinik für Innere Medizin III, Universitätsklinik , Albert-Einstein-Allee 23, 89081, Ulm, Deutschland. andreas.viardot@uniklinik-ulm.de.

|October 28, 2020

Summary

Chimeric antigen receptor (CAR) T-cell therapy represents a significant advancement in cancer treatment. Approved CAR T-cell drugs offer new hope for aggressive lymphoma and certain leukemias, with broader applications anticipated.

Keywords:

Aggressive lymphoma Chimeric antigen receptor Cytokine release syndrome Neurotoxicity

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Related Experiment Videos

Last Updated: Dec 3, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Area of Science:

Oncology
Immunotherapy
Cellular Therapy

Background:

Chimeric antigen receptor (CAR) T-cell therapy is a groundbreaking innovation in cancer medicine.
Recent approvals in the EU for relapsed/refractory aggressive lymphoma and pediatric/young adult acute lymphoblastic leukemia highlight its potential.

Purpose of the Study:

To review the current status and future prospects of CAR T-cell therapy in oncology.
To discuss the challenges and implications associated with the introduction of this novel therapeutic approach.

Main Methods:

Review of recent regulatory approvals and ongoing clinical trials for CAR T-cell therapies.
Analysis of regulatory, quality management, socioeconomic, and ethical considerations.

Main Results:

Two novel CAR T-cell drugs approved in the EU in August 2018 for specific hematological malignancies.
Ongoing clinical trials across numerous cancer types indicate expanding therapeutic potential.
Anticipated future approvals in mantle cell lymphoma and multiple myeloma.

Conclusions:

CAR T-cell therapy is poised to transform the treatment landscape for various cancers.
Addressing regulatory, quality, and socioeconomic challenges is crucial for widespread adoption.
Lifelong patient surveillance may be necessary due to the nature of "living drugs".